Experimental drug targets Hard-to-Treat salivary gland cancers
NCT ID NCT05884320
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether the drug sacituzumab govitecan can help control salivary gland cancer that has come back or spread to other parts of the body. About 30 adults whose cancer cannot be removed by surgery or cured with radiation will receive the drug through an IV. Researchers will monitor side effects and how well the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab govitecan (a drug given by IV)
- What this could lead to
- If it works, this could offer a new treatment option for people with salivary gland cancer that has come back or spread.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug can cause side effects like nausea, fatigue, and low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a targeted drug shrink rare salivary gland tumors?
- New drug cocktail targets genetic weakness in rare cancer
- Drug duo takes on rare head and neck tumors
- Rare sinus cancer study aims to clarify treatment outcomes
- New pill-chemo combo takes on hard-to-treat cancers